Englewood Hospital’s TAVR Program Receives Top Overall Quality Score from Society of Thoracic Surgeons and American College of Cardiology

Only Hospital in New Jersey to Achieve Highest Overall Rating for TAVR

October 28, 2024 – The Structural Heart and Valve Program at Englewood Hospital has received the top overall score for quality (a three-star rating) from The Society of Thoracic Surgeons (STS) and the American College of Cardiology (ACC) for transcatheter aortic valve replacement (TAVR).  

For the second year in a row, Englewood Hospital is the only hospital in New Jersey to achieve the highest overall rating for TAVR from the STS/ACC TVT Registry.

In achieving the highest rating, Englewood Hospital is recognized alongside NewYork-Presbyterian–Weill Cornell Medical Center, NewYork-Presbyterian–Columbia University Irving Medical Center, NYU Langone Health–Tisch Hospital, and Catholic Health–St. Francis Hospital & Heart Center, as the only hospitals in the tristate area to receive 3 stars for TAVR this rating period.

Englewood Health has been performing TAVR since it became FDA-approved for high-risk patients in 2012.

“Taking care of patients with advanced aortic valve disease is challenging, and achieving this top-quality score is a reflection of the commitment of our entire team to pursuing the best possible outcomes for our patients,” says Ramin Hastings, MD, medical director of the Structural Heart and Valve Program at Englewood Hospital. “This 3-star rating, based exclusively on clinical outcomes, is a testament to Englewood Hospital’s unmatched quality of care for TAVR patients in New Jersey.” 

As the premier clinical outcomes registry for transcatheter valve procedures, the STS/ACC TVT National Database helps hospitals and TAVR teams of interventional cardiologists, cardiothoracic surgeons, and cardiac imagers, assess and benchmark their performance to improve quality, safety, and patient outcomes. Englewood Hospital voluntarily submits TAVR clinical data to the STS/ACC, opting in for their public reporting as well. The recently published data covers TAVR cases from October 2020 through September 2023.